Prostate cancer diagnosis modernized – the genetic Stockholm3 test

Prostate cancer screening is undergoing a transformation. The USZ now offers the innovative genetic blood test Stockholm3, which uses various biomarkers for prostate cancer to improve early detection. The new biomarkers can detect pathological changes in the prostate at an early stage and thus improve the accuracy of the diagnosis.

Here at the USZ, you can have the scientifically based Stockholm3 blood test, which significantly improves the early detection of aggressive prostate cancer, carried out. It has been practiced in Sweden and Norway since 2017 and is now also available in other European countries.

Numerous scientific studies with a total of 75,000 participants have demonstrated the following advantages of the Stockholm3 test:

The Stockholm3 test

  • is detecting more cases of aggressive prostate cancer,
  • reduces the number of unnecessary prostate biopsies (removal of tissue from the prostate),
  • detects aggressive cancer even in men with a low PSA (prostate-specific antigen).

Who can take the Stockholm3 test?

The test is suitable for men between the ages of 45 and 75 who have not yet had prostate cancer and whose PSA value is above 1.5 ng/ml.

How much does Stockholm3 cost?

The costs of the Stockholm3 test, all associated consultations relating to the test at our clinic and the PSA test (if necessary) are generally covered by health insurance. The Stockholm3 test is invoiced by the laboratory in Switzerland.

How does Stockholm3 work?

The Stockholm3 test is a blood test. This can be carried out from a PSA value of 1.5 ng/ml. Five different proteins and over 100 genetic biomarkers for the genetic risk profile are analyzed in the blood. The previous diagnostic standard, the PSA (prostate-specific antigen), is also determined. These laboratory values are combined with clinical data such as age, previous biopsies and family history in a risk score for the detection of aggressive prostate cancer at an early stage.

From a PSA value of 1.5 ng/ml, we can send blood samples from our patients to a Swiss laboratory. The treating urologist receives a clear treatment recommendation after the analysis. This may include, for example, that the risk of aggressive prostate cancer is low and that further screening in 1-6 years is sufficient. Or she recommends using further diagnostic procedures such as MRI (magnetic resonance imaging) or tissue removal from the prostate (biopsy) to clarify whether cancer could be present. All results are discussed with the patient and the next steps are decided.

Infographic Stockholm3

Responsible specialist

Daniel Eberli, Prof. Dr. Dr. med.

Director of Department, Department of Urology

Tel. +41 44 255 54 01
Specialties: Prostate cancer: 3D prostate biopsies (MRI fusion, stereotactic), DaVinci robotics and laparoscopy, HIFU (High Intensity Focused Ultrasound), Robotic surgery (kidney and bladder), Treatment of benign prostate enlargement

For patients

If you would like a consultation for the Stockholm3 test, please fill out the contact form. During the consultation, we will discuss whether a Stockholm3 test is suitable for you.

Contact form

For referrering physicians

Easily assign your patients online.

University Hospital Zurich
Department of Urology
Frauenklinikstrasse 10
8091 Zurich

Tel. +41 44 255 54 40
Assign online

For international patients

Are you planning medical treatment in Switzerland? Would you like to have a Skype consultation? We are here for you!

Tel. +41 44 255 54 54
Contact us!

Responsible Department

Related diseases